What is the August 2024 PDUFAs Drug Approval Outlook?

The August 2024 PDUFAs Drug Approval Outlook provides insights into upcoming FDA drug approvals, highlighting key candidates, their indications, PDUFA dates, and probabilities of approval. This month features several promising therapies, including Afami-cel for advanced synovial sarcoma and HAV for vascular trauma, both with high probabilities of receiving FDA approval.

How does the PDUFA date affect drug approval timelines?

The PDUFA date, or Prescription Drug User Fee Act date, is a target date set by the FDA for reviewing new drug applications. It plays a crucial role in drug approval timelines, as it indicates when the FDA is expected to make a decision on a New Drug Application (NDA) or Biologics License Application (BLA). Delays can occur, but the PDUFA date provides a framework for stakeholders to anticipate approval outcomes.

What factors influence the probability of approval for drugs in the August 2024 PDUFAs?

The probability of approval for drugs listed in the August 2024 PDUFAs is influenced by several factors, including clinical trial results, FDA designations like priority review or breakthrough therapy, and the presence of significant unmet medical needs. For example, Afami-cel has a 70% probability of approval due to its promising clinical data and priority review status.

What are the implications of priority review status for drugs like HAV and TransCon PTH?

Priority review status indicates that the FDA recognizes a drug's potential to address unmet medical needs, expediting its review process. For drugs like HAV and TransCon PTH, this status not only enhances the likelihood of a faster approval but also reflects the FDA's acknowledgment of their significant therapeutic benefits based on clinical trial outcomes.

What challenges do drugs face during the PDUFA approval process?

Drugs can encounter various challenges during the PDUFA approval process, including the need for additional data, safety concerns, or manufacturing issues. For instance, LYMPHIR™ faced a Complete Response Letter from the FDA, requiring further data on manufacturing controls, which highlights the complexities involved in securing FDA approval despite promising clinical results.

August 2024 PDUFAs Drug Approval Outlook

Adaptimmune Therapeutics plc - Afami-cel

Indication: Advanced Synovial Sarcoma
PDUFA Date: August 4, 2024
Probability of Approval: 70%

Summary:
Afami-cel has received FDA priority review status, reflecting its potential to significantly improve treatment outcomes for patients with advanced synovial sarcoma. The SPEARHEAD-1 trial demonstrated a 39% objective response rate (ORR) and a median overall survival (OS) of 17 months, compared to less than 12 months historically. The FDA’s recognition of the significant unmet need and positive clinical data strongly support a high probability of approval.

Hedge Fund Holdings: 6 out of 34

Humacyte, Inc. - Human Acellular Vessel™ (HAV™)

Indication: Vascular Trauma
PDUFA Date: August 10, 2024
Probability of Approval: 75%

Summary:
HAV has shown promising results in clinical trials, demonstrating higher patency rates (90.2% vs. 78.9%), lower amputation rates (9.8% vs. 24.3%), and lower infection rates (2.0% vs. 8.4%) compared to synthetic grafts. The FDA granted priority review and RMAT designation, indicating its potential to improve the current standard of care. The inclusion of data from humanitarian use in Ukraine further strengthens the BLA submission.

Hedge Fund Holdings: 0 out of 34

Citius Pharmaceuticals, Inc. - LYMPHIR™ (Denileukin Diftitox)

Indication: Cutaneous T-cell lymphoma
PDUFA Date: August 13, 2024
Probability of Approval: 65%

Summary:
LYMPHIR™ has faced challenges, including a Complete Response Letter (CRL) from the FDA requiring additional data on manufacturing controls. However, the resubmitted BLA has been accepted, reflecting improvements in addressing FDA concerns. Clinical data showed an ORR of 36.2% and a clinical benefit rate up to 60% in different patient subgroups. Given the previous hurdles and improvements, the probability of approval is moderate.

Hedge Fund Holdings: 0 out of 34

Ascendis Pharma A/S - TransCon PTH

Indication: Hypoparathyroidism
PDUFA Date: August 14, 2024
Probability of Approval: 70%

Summary:
TransCon PTH has shown significant promise in managing hypoparathyroidism by improving calcium levels and reducing symptoms. Its priority review status by the FDA indicates recognition of its potential to meet significant unmet medical needs, supporting a high probability of approval.

Hedge Fund Holdings: 4 out of 34

Gilead Sciences, Inc. - Seladelpar

Indication: Primary biliary cholangitis (PBC)
PDUFA Date: August 14, 2024
Probability of Approval: 72%

Summary:
Seladelpar has demonstrated strong efficacy in clinical trials, improving liver biochemistry and symptoms in PBC patients. The FDA’s decision to grant priority review suggests that the drug could significantly benefit patients with limited treatment options. Key clinical trials have shown significant reductions in alkaline phosphatase (ALP) levels and improvements in pruritus, supporting its potential approval.

Hedge Fund Holdings: 0 out of 34

Intercept Pharmaceuticals, Inc. - Ocaliva (obeticholic acid)

Indication: Primary biliary cholangitis (PBC)
PDUFA Date: August 15, 2024
Probability of Approval: 68%

Summary:
Ocaliva has demonstrated efficacy in reducing alkaline phosphatase (ALP) levels, which is a critical biomarker in PBC treatment. It initially received accelerated approval for use in combination with ursodeoxycholic acid (UDCA) or as a monotherapy for those intolerant to UDCA. However, safety concerns, particularly related to liver-related adverse effects in patients with cirrhosis, have been significant. The current supplemental new drug application (sNDA) aims to provide additional data addressing these safety concerns. Given its previous approval and the additional data submitted, the probability of approval remains moderate but cautious due to ongoing safety issues.

Hedge Fund Holdings: 0 out of 34

Agios Pharmaceuticals, Inc. - Vorasidenib

Indication: IDH-mutant diffuse glioma
PDUFA Date: August 20, 2024
Probability of Approval: 75%

Summary:
Vorasidenib has shown substantial promise as a treatment for IDH-mutant diffuse glioma, demonstrating significant improvements in progression-free survival (PFS) and time to next intervention (TTNI) in the Phase 3 INDIGO trial. The drug has received fast track and breakthrough therapy designations from the FDA, underscoring its potential impact. The trial results revealed a median PFS of 27.7 months compared to 11.1 months with placebo, along with significant TTNI improvements. These strong efficacy results support a high probability of approval.

Hedge Fund Holdings: 3 out of 34 (Agios Pharmaceuticals)
Hedge Fund Holdings: 1 out of 34 (Royalty Pharma)

Regeneron Pharmaceuticals, Inc. - Linvoseltamab

Indication: Relapsed/Refractory Multiple Myeloma (R/R MM)
PDUFA Date: August 22, 2024
Probability of Approval: 72%

Summary:
Linvoseltamab, a bispecific antibody targeting BCMA and CD3, has shown high efficacy in heavily pretreated patients with relapsed/refractory multiple myeloma. The Phase 1/2 LINKER-MM1 trial demonstrated an objective response rate (ORR) of 71%, with deep responses including a 46% complete response rate. The drug has a manageable safety profile, with common adverse events such as cytokine-release syndrome, neutropenia, and anemia being manageable and mostly of lower grades. The drug has received FDA priority review status, which highlights its potential to meet significant unmet medical needs in this patient population.

Hedge Fund Holdings: 2 out of 34

Incyte Corporation - Axatilimab

Indication: Chronic Graft-Versus-Host Disease (GVHD)
PDUFA Date: August 28, 2024
Probability of Approval: 68%

Summary:
Axatilimab has shown promise in treating chronic graft-versus-host disease, a severe complication following bone marrow transplants. Clinical trials have demonstrated significant improvements in symptoms and overall response rates, with a manageable safety profile. The BLA has been granted priority review, underscoring its potential to address a critical unmet need. The drug has demonstrated strong efficacy and safety profiles in its clinical studies, which support its approval probability.

Hedge Fund Holdings: 2 out of 34 (Incyte Corporation)

Syndax Pharmaceuticals, Inc. - Axatilimab (SNDX-6352)

Indication: Chronic GVHD
PDUFA Date: August 28, 2024
Probability of Approval: 68%

Summary:
Syndax’s axatilimab (SNDX-6352) has also been evaluated for the treatment of chronic GVHD. The drug has shown strong clinical efficacy, similar to Incyte’s version, and has received priority review from the FDA. The data from clinical trials indicate significant improvements in patient outcomes, with a manageable safety profile, contributing to its high probability of approval.

Hedge Fund Holdings: 10 out of 34

Recent Updates

Recently added Catalysts